AVGO Research Note — The Evidence Bar Rises
Broadcom’s growth and AI backlog remain powerful, but a crowded tape and demanding valuation make the next evidence window unusually important.
CAMS Free Update
Market Structure: Old Leadership Fades as Rotation Holds — July 28, 2026
Broad sector participation is absorbing technology weakness, but narrow stock-level breadth keeps the market constructive and selective.
SPCX Research Note — Earnings Meets Supply
SpaceX operating progress meets SPCX’s unresolved post-IPO tape as first earnings and a large August share release test public-market demand.
WST Research Note — Growth Meets a Credibility Test
West Pharmaceutical’s strong quarter meets a harder test from valuation, market structure and unresolved oral-drug substitution risk.
MOH Research Note — The Beat Masks Strain
Molina’s earnings beat and raised outlook face a harder test from weak premium revenue, declining membership and sharply compressed margins.
ASML Research Note — Monopoly Quality Needs Confirmation
ASML’s monopoly remains intact, but bookings evidence and China-policy exposure must confirm the next phase of the equipment cycle.
MS Research Note — Franchise Quality Meets an Evidence Gap
Morgan Stanley’s improving returns support its franchise, while relative weakness and an unresolved wealth-margin bridge raise the evidence bar.
UNH Research Note — Better Headlines, Unresolved Costs
UnitedHealth’s better quarter did not settle the medical-cost debate as the shares reversed sharply despite broader health-care leadership.
Market Structure: Inflation Pressure Reshapes Leadership — July 27, 2026
Energy, health care, and financials lead as higher-rate expectations pressure consumer and communication groups across the current market tape.
LLY Research Note — Franchise Strength Meets Valuation Risk
Lilly’s incretin franchise remains powerful, while valuation, policy and access risks make the August 5 evidence window unusually important.